- Home
- OPAD vs COEP Comparison
OPAD vs COEP Comparison
Compare OPAD & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPAD
- COEP
- Stock Information
- Founded
- OPAD 2015
- COEP 2017
- Country
- OPAD United States
- COEP United States
- Employees
- OPAD N/A
- COEP N/A
- Industry
- OPAD Real Estate
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPAD Finance
- COEP Health Care
- Exchange
- OPAD Nasdaq
- COEP Nasdaq
- Market Cap
- OPAD 25.3M
- COEP 27.4M
- IPO Year
- OPAD N/A
- COEP N/A
- Fundamental
- Price
- OPAD $1.97
- COEP $9.81
- Analyst Decision
- OPAD Hold
- COEP
- Analyst Count
- OPAD 5
- COEP 0
- Target Price
- OPAD $2.38
- COEP N/A
- AVG Volume (30 Days)
- OPAD 148.4K
- COEP 37.8K
- Earning Date
- OPAD 08-04-2025
- COEP 08-15-2025
- Dividend Yield
- OPAD N/A
- COEP N/A
- EPS Growth
- OPAD N/A
- COEP N/A
- EPS
- OPAD N/A
- COEP N/A
- Revenue
- OPAD $794,159,000.00
- COEP $62,874.00
- Revenue This Year
- OPAD N/A
- COEP N/A
- Revenue Next Year
- OPAD $40.79
- COEP N/A
- P/E Ratio
- OPAD N/A
- COEP N/A
- Revenue Growth
- OPAD N/A
- COEP N/A
- 52 Week Low
- OPAD $0.91
- COEP $2.31
- 52 Week High
- OPAD $5.13
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- OPAD 77.35
- COEP 59.36
- Support Level
- OPAD $1.31
- COEP $7.25
- Resistance Level
- OPAD $1.52
- COEP $10.00
- Average True Range (ATR)
- OPAD 0.17
- COEP 0.55
- MACD
- OPAD 0.07
- COEP 0.27
- Stochastic Oscillator
- OPAD 89.36
- COEP 81.00
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.